Nanobiotix Newswire

Comprehensive Real-Time News Feed for Nanobiotix.

Results 1 - 20 of 45 in Nanobiotix

  1. Nanobiotix Receives First Approval To Start Phase 2/3 Registration...Read the original story

    Thursday Oct 16 | BioSpace

    NANOBIOTIX , a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that it has received approval from the French National Security Agency for Medicines and Health Products to start its Phase II/III registration trial of its lead product, NBTXR3, in patients with locally advanced Soft Tissue Sarcoma . Patients with locally advanced STS have very limited therapeutic options.

    Comment?

  2. Nanobiotix Receives First Approval to St ...Read the original story

    Thursday Oct 16 | The Financial Mirror

    NANOBIOTIX , a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that it has received approval from the French National Security Agency for Medicines and Health Products to start its Phase II/III registration trial of its lead product, NBTXR3, in patients with locally advanced Soft Tissue Sarcoma . Patients with locally advanced STS have very limited therapeutic options.

    Comment?

  3. European Commission opens the gate towards the implementation of Nanomedicine Translation HubRead the original story

    Wednesday Oct 15 | Science, Industry and Business

    ... need of assistance in specific areas of expertise. Coordinator: ETPN Secretariat c/o VDI/VDE-IT (DE) Consortium: Nanobiotix (FR), CEA-Leti (FR), Bioanalytik Muenster e.V. (DE), Tel-Aviv University (IL), Fondazione Don Carlo Gnocchi ONLUS (IT), and ...

    Comment?

  4. Nanobiotix Reaches The Second Milestone Payment Of Dedicated To...Read the original story

    Monday Oct 13 | BioSpace

    NANOBIOTIX , a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the second payment of a 1.144 k from Bpifrance as part as the funding granted to support the NICE consortium. Taking into account the development of the Strategic Industrial Innovation program and based on the completion of the first milestone "Etape clA 1", Bpifrance has proceed to transfer a 1.144 k to Nanobiotix.

    Comment?

  5. Onxeo reaches second milestone of BPIFrance grant dedicated to...Read the original story w/Photo

    Friday Oct 10 | Business Wire

    ... in phase III and the company expects to complete the study in 2016. In addition to Onxeo, the consortium includes Nanobiotix, developer of NBTXR3, a potentiator of radiation therapy in the local treatment of cancer; CEA-Leti, developer of the ...

    Comment?

  6. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Wednesday Oct 8 | Business Wire

    ... Market Out... )--PharmaEngine Inc. (TWO: 4162), a biopharmaceutical company developing new cancer treatments, and Nanobiotix S.A. (Euronext: NANO), a clinical-stage nanomedicine com... Research and Markets: Global Filling Equipment Market Outlook ...

    Comment?

  7. PharmaEngine, Nanobiotix Enter Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue SarcomaRead the original story w/Photo

    Wednesday Oct 8 | Business Wire

    PharmaEngine Inc. , a biopharmaceutical company developing new cancer treatments, and Nanobiotix S.A. , a clinical-stage nanomedicine company pioneering in novel approaches for local treatment of cancer, announced today that the companies had strengthened their collaboration by jointly conducting a global pivotal trial of NBTXR3 in soft tissue sarcoma in Europe and Asia. Nanobiotix expects recruitment of the first patient in Europe by the end of 2014.

    Comment?

  8. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Wednesday Oct 8 | Business Wire

    )--PharmaEngine Inc. (TWO: 4162), a biopharmaceutical company developing new cancer treatments, and Nanobiotix S.A. (Euronext: NANO), a clinical-stage nanomedicine com... Research and Markets: Global Filling Equipment Market Outlook 2019: Krones AG, ...

    Comment?

  9. PharmaEngine will join Nanobiotix' pivotal trial for NBTXR3 in...Read the original story

    Tuesday Oct 7 | PR-inside.com

    Small but heading for the big time PharmaEngine will join Nanobiotix' pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific PharmaEngine to make milestone payment to Nanobiotix in October 2014 to recognize the value created Paris, France, 8 October, 2014 - NANOBIOTIX , a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer today announces the update of the development plan for NBTXR3. Nanobiotix and its partner PharmaEngine Inc.,a biopharmaceutical company focusing on the development of in- licensed oncology drugs, reinforce their collaboration to obtain faster market authorization for NBTXR3 in the Asia-Pacific region.

    Comment?

  10. French Cancer Treatment Developer To Expand To U.S. With Boston OfficeRead the original story

    Tuesday Sep 23 | Banker & Tradesman

    Laurent Lvy, CEO of Nanobiotix, and Gov. Deval Patrick officially announced the opening of the company's U.S. affiliate during a ceremony on Sept. 19 at the U.S. embassy in Paris in the company of Susan Windham-Bannister, CEO and President of the Massachusetts Life Sciences Center.

    Comment?

  11. French biotech Nanobiotix to open 1st U.S. office in BostonRead the original story w/Photo

    Sep 23, 2014 | Business Journal

    Nanobiotix, a France-based developer of potential therapies to treat cancer, said it intends to open its first U.S. office in Boston.

    Comment?

  12. Nanobiotix Expands Operations Into The U.S.A. As Part Of Its International Development StrategyRead the original story

    Sep 22, 2014 | BioSpace

    Affiliate opened in the Massachusetts Life Sciences Center A senior pharmaceutical executive appointed as Vice President Corporate Development Paris, France, September 22, 2014 - NANOBIOTIX , a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the opening of its first US office in Boston, Massachusetts, the global center for life sciences.

    Comment?

  13. Nanobiotix Expands Operations into the USA as Part of Its International Development StrategyRead the original story

    Sep 22, 2014 | Freshnews

    NANOBIOTIX , a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the opening of its first US office in Boston, Massachusetts, the global center for life sciences. Laurent Levy, CEO of Nanobiotix, and Deval Patrick, Governor of Massachusetts state, officially announced the opening of the company's US affiliate during a ceremony on Friday September 19, 2014 at the US embassy in Paris, France, in the presence of Dr Susan Windham-Bannister, CEO and President of the Massachusetts Life Sciences Center.

    Comment?

  14. Gov. Patrick returning from European trade missionRead the original story w/Photo

    Sep 20, 2014 | KRNV-TV Reno

    Patrick said the trip was intended to expand opportunities between Massachusetts and European countries in the innovation economy, clean tech, digital gambling, financial services and education sectors. On Friday Patrick announced that Nanobiotix - a Paris-based nano-medicine company pioneering new approaches for cancer treatment - will open its first U.S. office in Massachusetts.

    Comment?

  15. Massachusetts Governor Deval PatrickRead the original story w/Photo

    Sep 20, 2014 | KVBC-TV Las Vegas

    Patrick said the trip was intended to expand opportunities between Massachusetts and European countries in the innovation economy, clean tech, digital gambling, financial services and education sectors. On Friday Patrick announced that Nanobiotix - a Paris-based nano-medicine company pioneering new approaches for cancer treatment - will open its first U.S. office in Massachusetts.

    Comment?

  16. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Sep 8, 2014 | Business Wire

    ... is excited to announce the launch of Voices in Life Sciences (VLS) at the 2014 D... )--Regulatory News : Nanobiotix (Paris:NANO) : Place de cotation : Euronext Paris Compartiment : Compartiment C Code ISIN : FR0011341205 Site web : ...

    Comment?

  17. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Sep 8, 2014 | Business Wire

    ... is excited to announce the launch of Voices in Life Sciences (VLS) at the 2014 D... )--Regulatory News : Nanobiotix (Paris:NANO) : Place de cotation : Euronext Paris Compartiment : Compartiment C Code ISIN : FR0011341205 Site web : ...

    Comment?

  18. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Aug 28, 2014 | Business Wire

    A ... )--The U.S. India Business Council led a delegation of medical device executives from Abbott, Baxter, Boston Scientific, Covidien, GE Healthcare, Johnson & John... )--Regulatory News : NANOBIOTIX , sociA tA franA aise pionniA re en nanomA decine dA veloppant NanoXray, une approche thA rapeutiqu... )--Regulatory ... (more)

    Comment?

  19. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Aug 28, 2014 | Business Wire

    ... from Abbott, Baxter, Boston Scientific, Covidien, GE Healthcare, Johnson & John... )--Regulatory News : NANOBIOTIX (Paris:NANO) (Euronext : NANO - ISIN: FR0011341205), sociA tA franA aise pionniA re en nanomA decine dA veloppant ...

    Comment?

  20. Recent Study: Brain Tumor - Pipeline Review, H2 2014Read the original story

    Jul 21, 2014 | SBWire

    ... from pipeline Companies Mentioned in this Report: Chong Kun Dang Pharmaceutical Corp., Pfizer Inc., Bayer AG, Nanobiotix, Hutchison MediPharma Limited, Siena Biotech S.p.A., Oncovir, Inc., DEKK-TEC, Inc., SignPath Pharma Inc, CalAsia ...

    Comment?